Back to top
more

Myriad Genetics (MYGN)

(Delayed Data from NSDQ)

$17.57 USD

17.57
1,452,620

-0.04 (-0.23%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $17.55 -0.02 (-0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks News

Myriad's (MYGN) New Acquisition to Boost Precision Oncology Arm

Myriad Genetics (MYGN) is set to acquire certain assets of IPG, including Precise Liquid, which is expected to be launched later this year.

Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now

Investors are optimistic about Myriad Genetics (MYGN) on robust testing volumes and strong solvency position.

Myriad Genetics' (MYGN) New Platform to Advance Cancer Care

Myriad Genetics' (MYGN) new MCRR platform advances patient care by combining structured clinical data with genetic and genomic results.

Myriad Genetics' (MYGN) New Partnerships Aid Amid FX Woes

Myriad Genetics (MYGN) continues to record strong revenue growth from companion diagnostics, including significant revenue share from its proprietary myChoiceCDx test.

Why Is Myriad (MYGN) Up 3% Since Last Earnings Report?

Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now

Investors are optimistic about Myriad Genetics (MYGN) on recent partnerships and growth in testing volumes.

Myriad Genetics (MYGN) Expands Pharma Services With New Pact

Myriad Genetics (MYGN) will market the Personalis ImmunoID NeXT ultra-comprehensive biomarker discovery platform to its pharmaceutical partners with a new collaboration.

Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Loss in Q3

Myriad Genetics' (MYGN) third-quarter 2023 revenues increase year over year, driven by strong testing volume improvement across all its businesses.

Myriad (MYGN) Reports Q3 Earnings: What Key Metrics Have to Say

The headline numbers for Myriad (MYGN) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Myriad Genetics (MYGN) Secures Key Milestones in Illumina Tie-Up

Myriad Genetics (MYGN) achieves significant milestones in its partnership with Illumina.

Myriad Genetics' (MYGN) New Deal to Use MRD Testing Platform

Myriad Genetics (MYGN) announces a collaboration with Memorial Sloan Kettering Cancer Center to study the use of MRD testing in breast cancer.

Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now

Investors are optimistic about Myriad Genetics (MYGN) on improvement in testing volume across all its businesses.

Why Is Amicus Therapeutics (FOLD) Down 6.8% Since Last Earnings Report?

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Myriad Genetics (MYGN) Teams Up to Assess Breast Cancer Risk

Myriad Genetics (MYGN) announces collaboration with Onsite Women's Health to develop a breast cancer risk assessment program.

Myriad Genetics (MYGN) Adds ARR to Prolaris Biomarker Test

Myriad Genetics (MYGN) announces the integration of ARR into the Prolaris prostate cancer prognostic test.

Accuray's (ARAY) Treatment Options to be Boosted Post FDA's Nod

Accuray's (ARAY) latest regulatory approval is likely to improve breast cancer treatment.

Myriad Genetics (MYGN) Unveils GeneSight Test Enhancement

Myriad Genetics' (MYGN) GeneSight report will contain details on how a patient's smoking history may affect their metabolism of certain medications.

Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Q2 Loss

Strong testing volume improvement across all businesses drives Myriad Genetics' (MYGN) Q2 performance.

Myriad (MYGN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Myriad (MYGN) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Myriad Genetics (MYGN) Reports Q2 Loss, Misses Revenue Estimates

Myriad (MYGN) delivered earnings and revenue surprises of 20% and 1.37%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Myriad Genetics (MYGN) Test Volume Rises Amid Margin Woe

Myriad Genetics' (MYGN) collaboration with medical imaging provider, SimonMeD, is expected to advance precision medicine with a new hereditary cancer assessment program.

Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now

Investors are optimistic about Myriad Genetics (MYGN) due to the performance of its oncology business and product launches.

Myriad Genetics' (MYGN) New Pact to Use MRD Testing Platform

Myriad Genetics (MYGN) announces research collaboration with MD Anderson on metastatic RCC with its high-definition MRD research testing platform based on whole-genome sequencing.

Myriad Genetics (MYGN) Adds New Test to Oncology Portfolio

Myriad Genetics (MYGN) expands Precise Oncology Solutions portfolio by adding a new biomarker test.

Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now

Myriad Genetics (MYGN) is likely to benefit from testing volumes across product segments and the latest partnerships, reflecting a positive share price movement.